Dry powder inhalers and the right things to remember: A concept review

Multidisciplinary Respiratory Medicine

Volumn 10, Issue 1, 2015, Pages

  Dal Negro, Roberto W ^a,b  

^a National Centre of Studies of Pharmacoeconomics and Respiratory Pharmacoepidemiology (CESFAR)   (Italy)

^b Research and Clinical Governance   (Italy)

Author keywords

Dose consistency; Dry powder inhalers; Inhalation devices; Inspiratory flow resistance; Respiratory drug effectiveness

Indexed keywords

DISPERSION; DRY POWDER INHALER; FLOW RATE; HUMAN; INHALATION; MEASUREMENT PRECISION; METERED DOSE INHALER; REPRODUCIBILITY; RESPIRATORY AIRFLOW; REVIEW; SOFT MIST INHALER;

EID: 84949422610     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/s40248-015-0012-5     Document Type: Review

References (23)

1. Virchow JC. Guidelines versus clinical practice - which therapy and which device. Respir Med. 2004; 98(suppl B):S28-34.
2. Virchow JC, Crompton GK, Dal Negro RW, Pedersen S, Magnan A, Seidemberg J., et al. Importance of inhaler devices in the management of airway diseases. Respir Med. 2008;102:10-9.
3. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75:18-25.
4. Newman SP, Busse WW Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96:293-304.
5. Chapman KR, Fogarty CM, Peckitt C, Lassen C., Jadayel D, Dederichs J, et al Delivery characteristics and patients' handling of two single-dose dry powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353-63.
6. O'Connor BJ. The ideal inhaler: design and characteristics to improve outcomes. Respir Med. 2004;98(suppl A):S10-6.
7. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl. 1982;119:101-4.
8. Jackson WF. Inhalers in asthma. The new perspective. Harwell, Oxfordshire: Clinical Vision Ltd; 1995. p. 1-56.
9. Brocklebank D, Ram F, Wright J., Barry P, Cates C, Davies L., et al. Comparison of effectiveness of inhaler devices in asthma and chronic obstructive airway disease: a systematic review of the literature. Health Technol Assess. 2001;5(26):1-149.
10. Terzano C. Dry powder inhaler and the risk of error. Respiration. 2008;75:14-5.
11. Kruger P, Ehrlein, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers. Munich, Germany: Oral presentation at the European Respiratory Society Annual Meeting, September 6th-10th, 2014, proceedings.
12. Compton C, McBryan D, Bucchioni E, Patalano F. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2013;26:562-73.
13. Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66:309-17.
14. Al Showair R.A., Tarsin WY, Assi K.H., Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101:2395-401.
15. Janssen W, Van den Brande P, Hardeman E, De Langhe E, Philps T, Troosters T, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31:78-83.
16. Dal Negro R.W., Bonadiman L, Tognella S., Briccolo FP, Turco P. Extent and prevalence of cognitive dysfunction in chronic obstructive pulmonary disease, chronic non-obstructive bronchitis, and in asymptomatic smokers, compared to normal reference values. Int J Chron Obstruct Pulmon Dis. 2014;9:675-83.
17. Richter K. Successful use of DPI systems in asthmatic patients - key parameters. Respir Med. 2004;98(suppl B):522-7.
18. Richter K. Severe asthmatic patients generate significantly different peak expiratory flows through two different drug powder inhalers. Glasgow, Scotland: Poster at the European Respiratory Society Annual Meeting; 2004.
19. Munzel U, Marshall K, Fyrnis B., Wedel M. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers. Curr Med Res Opin. 2005;21:827-33.
20. Everard M, Devadason S, LE Souef PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbohaler. Respir Med. 1997;91:624-8.
21. Usmani OS, Biddiscombe MF, Barnes PJ Regional lung deposition and bronchodilator response as a function of beta-2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497-504.
22. Kohler D. The Novolizer: overcoming inherent problems of other dry powder inhalers. Respir Med. 2004;98(suppl A):S17-21.
23. Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multidose dry powder inhaler. Intern J Clin Pract. 2012; 66: 309-17.